Xynomic Pharmaceutical Holdings Inc. (XYNO)
Stock Price:
$2.08 USD
0.65 (45.63%)
Updated Oct 23, 2020 3:31 PM EDT - Market closed
Key Info
| Market Cap |
96.37M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-25.10M |
| Shares Out |
46.27M |
| EPS (ttm) |
-4.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$2.08 |
| Previous Close |
$1.43 |
| Change ($) |
0.65 |
| Change (%) |
45.63% |
| Day's Open |
2.08 |
| Day's Range |
2.08 - 2.08 |
| Day's Volume |
200 |
| 52-Week Range |
0.2 - 4.29 |
More Stats
| Market Cap |
96.37M |
| Enterprise Value |
96.68M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
46.27M |
| Float |
6.40M |
| EPS (basic) |
-0.83 |
| EPS (diluted) |
-4.25 |
| FCF / Share |
-0.33 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
622 |
| Short Ratio |
0.01 |
| Short % of Float |
0.01% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
44.89 |
| Revenue |
n/a |
| Operating Income |
-25.04M |
| Net Income |
-25.10M |
| Free Cash Flow |
-10.72M |
| Net Cash |
-312,239 |
| Net Cash / Share |
-0.01 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-489.08% |
| ROE |
n/a |
| ROIC |
203.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -25.04 | -28.57 | -5.45 |
| Net Income | -25.10 | -28.59 | -5.45 |
| Shares Outstanding | 32.28 | 8.17 | 8.83 |
| Earnings Per Share | -0.83 | -3.85 | -0.76 |
| Operating Cash Flow | -10.67 | -14.72 | -5.36 |
| Capital Expenditures | -0.05 | -0.18 | - |
| Free Cash Flow | -10.72 | -14.90 | -5.36 |
| Cash & Equivalents | 0.09 | 4.75 | 0.10 |
| Total Debt | 0.40 | - | 0.03 |
| Net Cash / Debt | -0.31 | 4.74 | 0.07 |
| Assets | 0.94 | 5.46 | 0.24 |
| Liabilities | 23.50 | 17.65 | 0.89 |
| Book Value | -22.56 | -20.09 | -5.73 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Xynomic Pharmaceutical Holdings Inc. |
| Country |
China |
| Employees |
27 |
| CEO |
Yinglin Mark Xu |
Stock Information
| Ticker Symbol |
XYNO |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: XYNO |
Description
Xynomic Pharmaceuticals Holdings, a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.